MedTrace Logo

OTIVACTO Spain Non Interventional Study

NCT02927795 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 257

Last updated 2019-09-30

Study results available
· View outcomes & findings →

Summary

This is a self-controlled study design enrolling consented COPD patients who will be treated with Spiolto® Respimat® according to the approved SmPC. Patients will be enrolled consecutively and will be followed over an observational period of approx. 6 weeks.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

  • Mireia Canals, +34607550925 · [email protected]

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-26
Primary Completion
2018-09-18
Completion
2018-09-18

Countries

  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02927795 on ClinicalTrials.gov